CRITERIA FOR USE: Requires Prior Authorization by Medical Director or Designee
|
|
- Ethan King
- 5 years ago
- Views:
Transcription
1 What s New Medical Pharmaceutical Plicy September Updates 2017 MBP Radicava (edaravne)- New Plicy CRITERIA FOR USE: Requires Prir Authrizatin by Medical Directr r Designee Radicava (edaravne) will be cnsidered medically necessary when ALL f the fllwing criteria are met: Prescriptin written by r in cnsultatin with a neurlgist AND Medical recrd dcumentatin f a diagnsis f ALS (amytrphic lateral sclersis) AND Medical recrd dcumentatin f baseline functinal status (as evidenced by a scring system such as ALSFRS-R, r by physician dcumentatin f subjective reprts n speech, mtr functin, pulmnary functin, etc.) AND Medical recrd dcumentatin that Radicava is being given in cmbinatin with riluzle OR intlerance r cntraindicatin t riluzle AUTHORIZATION DURATION: Initial apprval will be fr 12 mnths r less if the reviewing prvider feels it is medically apprpriate. Subsequent apprvals will be fr an additinal 12 mnths r less if the reviewing prvider feels it is medically apprpriate and will require the fllwing criteria. Medical recrd dcumentatin that member is tlerating and cmpliant with prescribed edaravne regimen AND Medical recrd dcumentatin f regular physician fllw-up Quantity Limit: Initial Cycle: 2800mL per 28 days (28 [30mg/100mL] bags per 28 days) Subsequent Cycles: 2000mL per 28 days (20 [30mg/100mL] bags per 28 days) MBP Ocrevus (crelizumab)- New Plicy CRITERIA FOR USE: Requires Prir Authrizatin by Medical Directr r Designee Ocrevus (crelizumab) will be cnsidered medically necessary when ALL f the fllwing criteria are met: Medical recrd dcumentatin f age > 18 years AND Medical recrd dcumentatin Ocrevus is prescribed by a neurlgist AND Medical recrd dcumentatin f a diagnsis f primary prgressive MS (PPMS) OR Medical recrd dcumentatin f a diagnsis f a relapsing frm f multiple sclersis AND Fr members with a diagnsis f a relapsing frm f multiple sclersis, medical recrd dcumentatin f therapeutic failure n, intlerance t, r cntraindicatin t three frmulary alternatives. AUTHORIZATION DURATION: Initial apprval will be fr 12 mnths r less if the reviewing prvider feels it is medically apprpriate. Subsequent apprvals will be fr an additinal 12 mnths r less if the reviewing prvider feels it is medically apprpriate and will require medical recrd dcumentatin f cntinued disease imprvement r lack f disease prgressin. The medicatin will n lnger be cvered if patient experiences txicity r wrsening f disease. Quantity Limit: Initial authrizatin: 12 mnth duratin with quantity limit f 3 dses Re-authrizatin: 12 mnth duratin with quantity limit f 2 dses 1
2 MBP Imfinzi (durvalumab)- New Plicy CRITERIA FOR USE: Requires Prir Authrizatin by Medical Directr r Designee Imfinzi (durvalumab) will be cnsidered medically necessary when ALL f the fllwing criteria are met: 1. Urthelial Carcinma Medical recrd dcumentatin that patient is 18 years f age AND Medical recrd dcumentatin f a diagnsis f lcally advanced r metastatic urthelial carcinma AND ne f the fllwing: Disease prgressin during r fllwing platinum-cntaining chemtherapy OR Disease prgressin within 12 mnths f neadjuvant r adjuvant treatment with platinum-cntaining chemtherapy AUTHORIZATION DURATION: Initial apprval will be fr 6 mnths r less if the reviewing prvider feels it is medically apprpriate. Subsequent apprvals will be fr an additinal 12 mnths r less if the reviewing prvider feels it is medically apprpriate and will require medical recrd dcumentatin f cntinued disease imprvement r lack f disease prgressin. The medicatin will n lnger be cvered if patient experiences txicity r wrsening f disease. MBP 57.0 Tysabri (natalizumab)- Criteria Updated Tysabri (natalizumab) will be cnsidered medically necessary when all f the fllwing criteria are met: 1. Relapsing Multiple Sclersis Tysabri is cnsidered medically necessary fr the treatment f relapsing frms f multiple sclersis relapsing multiple sclersis when the fllwing criteria are met: Medical recrd dcumentatin f member being established n and respnding t Tysabri fr at least 60 days prir t their effective date with the plan OR Medical recrd dcumentatin f a diagnsis f a relapsing frm f multiple sclersis relapsing/remitting multiple AND Medical recrd dcumentatin that the patient 18 years r lder AND Medical recrd dcumentatin that Tysabri is being prescribed by a neurlgist AND Patient is enrlled in a risk-minimizatin prgram, called the TOUCH Prescribing Prgram, AND Physician dcumentatin that Tysabri is being used as mntherapy is prvided. AND Medical recrd dcumentatin that the member has been tested fr anti-jcv antibdy prir t start f Tysabri therapy. If patient is anti-jcv antibdy psitive, medical recrd dcumentatin that benefits f drug utweigh the risks f prgressive multifcal leukencephalpathy (PML) and patient is aware f increased PML risk AND Medical recrd dcumentatin f therapeutic failure n, cntraindicatin t, r intlerance t tw frmulary alternatives. NOTE: Accrding t the American Academy f Neurlgy recmmendatin, Tysabri may be cnsidered as a first line therapy in individuals with relapsing remitting multiple sclersis wh exhibit particularly aggressive initial curse f disease and in whm the ptential benefit is felt t utweigh the risk. Patients with a pr prgnsis/aggressive disease include thse with a heavy T2 lesin lad, lesins in brain stem, cerebellum, and spinal crd. 2
3 LIMITATIONS: Cannt be used in cmbinatin with immunsuppressants (i.e. 6-mercaptpurine, azathiprine, cyclsprine, methtrexate) r inhibitrs f TNF-alpha AUTHORIZATION DURATION: Initial authrizatin and reauthrizatins fr MS will be fr a perid f ne (1) year. Fr re-authrizatin, medical recrd dcumentatin f patient adherence t medicatin and imprvement in signs and symptms f multiple sclersis while n Tysabri therapy will be required. Fr patients wh were previusly anti-jcv antibdy negative, medical recrd dcumentatin that physician has re-tested fr anti-jcv antibdy status within the last 12 mnths. Fr patients wh were anti-jcv antibdy psitive at baseline r n re-test, medical recrd dcumentatin that benefits f cntinuing drug utweigh risks. MBP 62.0 Remdulin IV (treprstinil sdium)- Criteria Updated Remdulin IV (treprstinil sdium) will be cnsidered medically necessary when all f the fllwing criteria are met: Must be prescribed by a pulmnlgist r cardilgist; and Physician prvided dcumentatin f a diagnsis f class 4 pulmnary arterial hypertensin; r Physician prvided dcumentatin f a diagnsis f class 2 r 3 pulmnary arterial hypertensin with therapeutic failure n, intlerance t r cntraindicatin t Revati and Ventavis; r Individuals wh require transitin frm Fllan, t reduce the rate f clinical deteriratin. The risks and benefits f each drug shuld be carefully cnsidered prir t transitin MBP 82.0 Jevtana (cabazitaxel)- Criteria Updated Jevtana (cabazitaxel) will be cnsidered medically necessary when all f the fllwing criteria are met: 1. Metastatic Hrmne- Resistant Prstate Cancer Physician prvided dcumentatin f a diagnsis f metastatic hrmne-refractry prstate cancer; and Physician prvided dcumentatin f abdminal, chest r pelvic MRI r CT scan t rule ut neurendcrine invlvement: and Is given in cmbinatin with ral prednisne 10mg daily thrughut treatment with Jevtana; and Physician prvided dcumentatin f neutrphil cunt greater than 1500 cells/mm 3 ; and Physician prvided dcumentatin f therapeutic failure n, intlerance t, r cntraindicatin t a dcetaxel-based regimen 3
4 MBP Injectable Antipsychtic Medicatins- Criteria Updated Prir authrizatin requirement applies nly t new starts. Insured individuals wh have been n Invega Trinza, Invega Sustenna, Aristada, Abilify Maintena, Zyprexa Relprevv, r Risperdal Cnsta IM Injectin prir t cming n t the Plan will be grandfathered and can cntinue t receive therapy. The fllwing Injectable Antipsychtic Medicatins (n Invega Trinza, Invega Sustenna, Aristada, Abilify Maintena, Zyprexa Relprevv, r Risperdal Cnsta) will be cnsidered medically necessary when the fllwing criteria are met: - Medical recrd dcumentatin that the patient is 18 years f age r lder AND - Medical recrd dcumentatin f a histry f pr adherence t ral medicatins and dcumentatin that educatin t imprve adherence has been attempted AND - Medical recrd dcumentatin f use fr an FDA apprved indicatin. Abilify Maintena Schizphrenia Aristada Schizphrenia Invega Sustenna Schizphrenia r Schizaffective disrders as mntherapy and as an adjunct t md stabilizers r antidepressants Invega Trinza Schizphrenia Risperdal Cnsta Schizphrenia r Biplar I Disrder as mntherapy r as adjunctive therapy t lithium r valprate Zyprexa Relprevv Schizphrenia - In additin: The fllwing criteria shuld apply t Invega Trinza: Medical recrd dcumentatin that the patient has been adequately treated with Invega Sustenna fr at least 4 mnths. GRANDFATHER PROVISION Geisinger Health Plan will grandfather prescriptins fr nn-frmulary medicatins r thse frmulary medicatins requiring prir authrizatin within quantity limits when there is an n-line prescriptin drug claim histry shwing 30 days use f the requested medicatin within the previus 90 days. If there is n n-line claim, the prescribing prvider shuld request a prir authrizatin. Medical recrd dcumentatin shwing the member receiving the requested medicatin fr at least 30 days within the previus 90 days must be prvided. LIMITATIONS: The fllwing quantity limits shuld apply (please enter claims payment nte, when entering authrizatin) - Abilify Maintena One syringe r vial per 28 days - Aristada One syringe per 28 days (441mg/1.6ml, 662mg/2.4ml, 882mg/3.2ml strength), ne syringe per 56 days (1064mg/3.9ml strength) - Invega Sustenna tw syringes per 1 week, then ne syringe per 28 days thereafter Enter claims payment nte as fllws t accunt fr lading dse in the first week: - Rx Cunt f 1 apprved by GPID fr 234 mg, quantity limit 1 - Rx Cunt f 1 apprved by GPID fr 156 mg, quantity limit 1 - Open-ended authrizatin fr quantity limit 1 syringe per mnth, request t be apprved by GPID fr the prescribed strength. - Invega Trinza One syringe per 84 days (3 mnths) - Risperdal Cnsta Tw vials per 28 days - Zyprexa Relprevv Tw vials per 28 days 4
5 MBP Keytruda (pembrlizumab) - Criteria Updated Keytruda (pembrlizumab) will be cnsidered medically necessary when all f the fllwing criteria are met: 1. Unresectable r Metastatic Melanma Medical recrd dcumentatin that patient is 18 years f age AND Medical recrd dcumentatin f a diagnsis f unresectable r metastatic melanma AND Medical recrd dcumentatin that Keytruda is nt being used in cmbinatin with any ther agents fr the treatment f unresectable r metastatic melanma. 2. Metastatic Nn-Small Cell Lung Cancer Medical recrd dcumentatin that patient is 18 years f age AND Medical recrd dcumentatin f a diagnsis f metastatic NSCLC meeting ne f the fllwing situatins: Medical recrd dcumentatin that Keytruda is being given as mntherapy AND Medical recrd dcumentatin that tumrs have high PD-L1 expressin (Tumr Prprtin Scre (TPS) 50% as determined by an FDA-apprved test AND Medical recrd dcumentatin that tumrs d nt have EGFR r ALK genmic tumr aberratins OR Medical recrd dcumentatin that Keytruda is being given as mntherapy AND Medical recrd dcumentatin that tumrs express PD-L1 (TPS) 1% as determined by an FDA-apprved test AND Medical recrd dcumentatin f disease prgressin n r after platinum-cntaining chemtherapy AND Fr patients with EGFR r ALK genmic tumr aberratins: medical recrd dcumentatin f disease prgressin n FDA-apprved therapy fr these aberratins prir t receiving Keytruda. OR Medical recrd dcumentatin f metastatic nnsquamus NSCLC AND Medical recrd dcumentatin that Keytruda will be given in cmbinatin with pemetrexed AND carbplatin 3. Head and Neck Squamus Cell Carcinma Medical recrd dcumentatin that patient is 18 years f age AND Medical recrd dcumentatin f a diagnsis f Head and Neck Squamus Cell Carcinma that is recurrent r metastatic and had disease prgressin n r after platinum-cntaining chemtherapy 4. Classical Hdgkin Lymphma Medical recrd dcumentatin f Classical Hdgkin Lymphma AND One f the fllwing: a. Medical recrd dcumentatin f a diagnsis f refractry Classical Hdgkin Lymphma OR b. Medical recrd dcumentatin f relapse fllwing three (3) r mre prir lines f therapy 5. Micrsatellite Instability-High Cancer 5
6 Medical recrd dcumentatin f unresectable r metastatic micrsatellite instability-high (MSI-H) r mismatch repair deficient (dmmr) slid tumrs OR clrectal cancer AND Fr slid tumrs: Medical recrd dcumentatin f prgressin fllwing prir treatment(s) AND Medical recrd dcumentatin f n satisfactry alternative treatment ptins Fr clrectal cancer: Medical recrd dcumentatin f prgressin fllwing treatment with flurpyrimidine, xaliplatin, and irintecan 6. Urthelial Carcinma Medical recrd dcumentatin that patient is 18 years f age AND Medical recrd dcumentatin f lcally advanced r metastatic urthelial carcinma AND Medical recrd dcumentatin f ne f the fllwing: Disease prgressin during r fllwing platinum-cntaining chemtherapy OR Disease prgressin within 12 mnths f neadjuvant r adjuvant treatment with platinum-cntaining chemtherapy OR Patient is nt eligible cisplatin-cntaining chemtherapy* *Nte: In clinical trials, patients wh were nt cnsidered cisplatin-eligible had the fllwing characteristics: baseline creatinine clearance f <60 ml/min, ECOG perfrmance status f 2, ECOG 2 and baseline creatinine clearance f <60 ml/min, ther reasns (Class III heart failure, Grade 2 r greater peripheral neurpathy, and Grade 2 r greater hearing lss). AUTHORIZATION DURATION: Initial apprval will be fr 6 mnths r less if the reviewing prvider feels it is medically apprpriate. Subsequent apprvals will be fr an additinal 12 mnths r less if the reviewing prvider feels it is medically apprpriate and will require medical recrd dcumentatin f cntinued disease imprvement r lack f disease prgressin. The medicatin will n lnger be cvered if patient experiences txicity r wrsening f disease. MBP Opdiv (nivlumab)- Criteria Updated Opdiv (nivlumab) will be cnsidered medically necessary when all f the fllwing criteria are met: 1. Melanma Medical recrd dcumentatin that patient is > 18 years f age AND Medical recrd dcumentatin f a diagnsis f unresectable r metastatic melanma AND Medical recrd dcumentatin that Opdiv is nt being used in cmbinatin with any ther agents fr the treatment f unresectable r metastatic melanma (with the exceptin f ipilimumab). 2. Nn-Small Cell Lung Cancer (NSCLC) Medical recrd dcumentatin that patient is > 18 years f age AND Medical recrd dcumentatin f a diagnsis f metastatic nn-small cell lung cancer (NSCLC) with disease prgressin while n r after platinum-based chemtherapy AND Medical recrd dcumentatin that Opdiv is nt being used in cmbinatin with any ther agents fr the treatment f metastatic nn-small cell lung cancer (NSCLC) 3. Renal Cell Carcinma Medical recrd dcumentatin f use as a single agent fr relapse r fr surgically unresectable advanced r metastatic renal cell carcinma AND 6
7 Medical recrd dcumentatin f a therapeutic failure n r intlerance t prir anti-angigenic therapy, including, but nt limited t, Sutent (sunitinib), Vtrient (pazpanib), Inlyta (axitinib), Nexavar (srafenib), Avastin (bevacizumab), Afinitr (everlimus), r Trisel (temsirlimus). 4. Classical Hdgkin Lymphma (CHL) Medical recrd dcumentatin that patient is > 18 years f age AND Medical recrd dcumentatin f a diagnsis f classical Hdgkin lymphma (CHL) that has relapsed r prgressed after: Autlgus hematpietic stem cell transplantatin and pst-transplantatin brentuximab vedtin (Adcetris). OR Three (3) r mre lines f systemic therapy that includes autlgus HSCT 5. Squamus Cell Carcinma f the Head and Neck (SCCHN) Medical recrd dcumentatin that patient is 18 years f age AND Medical recrd dcumentatin f a diagnsis f recurrent r metastatic squamus cell carcinma f the head and neck AND Medical recrd dcumentatin f disease prgressin while n r after receiving a platinumbased therapy 6. Urthelial Carcinma Medical recrd dcumentatin that patient > 18 years f age AND Medical recrd dcumentatin f a diagnsis f lcally advanced r metastatic urthelial carcinma AND ne f the fllwing: Disease prgressin during r fllwing platinum-cntaining chemtherapy OR Disease prgressin within 12 mnths f neadjuvant r adjuvant treatment with platinum-cntaining chemtherapy AND Medical recrd dcumentatin that Opdiv is NOT being used in cmbinatin with any ther agent AUTHORIZATION DURATION: Initial apprval will be fr 6 mnths r less if the reviewing prvider feels it is medically apprpriate. Subsequent apprvals will be fr an additinal 6 12 mnths r less if the reviewing prvider feels it is medically apprpriate and will require medical recrd dcumentatin f cntinued disease imprvement r lack f disease prgressin. The medicatin will n lnger be cvered if patient experiences txicity r wrsening f disease. The fllwing plicies were reviewed with n changes: MBP 2.0 Synagis (palivizumab) MBP 15.0 Zevalin (Ibritummab) MBP 36.0 Abraxane (paclitaxel prtein bund particles) MBP 40.0 Orencia IV (abatacept) MBP 48.0 Rituxan (rituximab) MBP 53.0 Eraxis (anidulafungin) MBP 68.0 Nplate (rmiplstim) MBP 74.0 Cimzia (certlizumab pegl) 7
8 MBP 76.0 Actemra IV (tcilizumab) MBP Simpni Aria (glimumab) MBP Lemtrada (alemtuzumab) MBP Cresemba IV (isavucnaznium sulfate) MBP Unituxin (dinutuximab) MBP Cinqair (reslizumab) 8
MBP 40.0 Orencia IV (abatacept)- Updated policy
What s New Medical Pharmaceutical Plicy Nvember 2018 Updates MBP 5.0 Remicade (infliximab), Inflectra (infliximab-dyyb), Renflexis (infliximab-abda)- Updated plicy Fr Treatment f Rheumatid Arthritis: Must
More informationXX Keytruda 100 MG/4ML SOLN (MERCK SHARP & DOHME)
Plicy Medical Plicy Manual Apprved: D Nt Implement Until 1/31/19 Pembrlizumab NDC CODE(S) 00006-3026-XX Keytruda 100 MG/4ML SOLN (MERCK SHARP & DOHME) DESCRIPTION Pembrlizumab is a human prgrammed death
More informationWhat s New Medical Pharmaceutical Policy September 2018 Updates MBP Site of Care- New policy
What s New Medical Pharmaceutical Plicy September 2018 Updates MBP 181.0 Site f Care- New plicy DESCRIPTION: Specific intravenus and injectable drugs must meet applicable medical necessity criteria fr
More informationDESCRIPTION: Zemdri (plazomicin) is an aminoglycoside, which acts by binding to bacterial 30S ribosomal subunit, inhibiting protein synthesis.
What s New Medical Pharmaceutical Plicy March 2019 Updates MBP 187.0 Zemdri (plazmicin)- New plicy DESCRIPTION: Zemdri (plazmicin) is an aminglycside, which acts by binding t bacterial 30S ribsmal subunit,
More informationXX Abraxane 100 MG SUSR (CELGENE CORP)
Plicy Medical Plicy Manual Apprved: D Nt Implement Until 1/31/19 Paclitaxel (Prtein-Bund) NDC CODE(S) 68817-0134-XX Abraxane 100 MG SUSR (CELGENE CORP) DESCRIPTION Paclitaxel is a natural prduct with antitumr
More informationXX Abraxane 100 MG SUSR (CELGENE CORP
Medical Manual Apprved Revised: D Nt Implement until 6/30/2019 Paclitaxel (Prtein-Bund) NDC CODE(S) 68817-0134-XX Abraxane 100 MG SUSR (CELGENE CORP DESCRIPTION Paclitaxel is a natural prduct with antitumr
More informationRituxan (rituximab) Effective Date: 10/01/2015. Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage
Rituxan (rituximab) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Effective Date: 10/01/2015 POLICY A. INDICATIONS The indicatins belw including FDA-apprved indicatins and cmpendial uses
More informationFolotyn (pralatrexate)
Fltyn (pralatrexate) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/2018TBD03/01/2017 POLICY A. INDICATIONS The indicatins
More informationSolid Organ Transplant Benefits to Change for Texas Medicaid
Slid Organ Transplant Benefits t Change fr Texas Medicaid Infrmatin psted February 13, 2015 Nte: All new and updated prcedure cdes and their assciated reimbursement rates are prpsed benefits pending a
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Orencia (abatacept) Applicable Medical Benefit x Effective: 2/21/18 Pharmacy- Frmulary 1 x Next Review: 12/18 Pharmacy- Frmulary 2 x Date f Origin: 11/28/06 Pharmacy- Frmulary 3/Exclusive
More informationo Prostanoids/prostacyclin therapies (oral and inhaled) o Inhaled agents: Ventavis, Tyvaso Page 1 of 5 Revised 02/17/17
Request fr Prir Authrizatin Pulmnary Arterial Hypertensin (PAH) Agents (Oral and Inhaled) Website Frm www.highmarkhealthptins.cm Submit request via: Fax - 1-855-476-4158 All requests fr Pulmnary Arterial
More informationRequest for Prior Authorization for Click here to enter text. Website Form Submit request via: Fax
Request fr Prir Authrizatin fr Click here t enter text. Website Frm www.highmarkhealthptins.cm Submit request via: Fax - 1-855-476-4158 Updated: 05/2018 DMMA Apprved: 05/2018 All requests fr Intravenus
More informationAPPENDIX A Certification of Advanced Disease:
APPENDIX A Certificatin f Advanced Disease: Name: DOB: Member ID: Name f Palliative Care Prgram: A. General Criteria: Check each f the fllwing that apply (All needed fr eligibility). Patient wh is likely
More informationNew Exception Status Benefits
FEBRUARY 2019 Nva Sctia Frmulary Updates New Exceptin Status Benefits Prcysbi (cysteamine bitartrate) Nucala (meplizumab) Ocaliva (betichlic acid) Ravicti (glycerl phenylbutyrate) Taltz (ixekizumab) Criteria
More informationAbraxane (paclitaxel protein-bound particles) (Intravenous)
Abraxane (paclitaxel prtein-bund particles) (Intravenus) Last Review Date: 5/30/2017 Date f Origin: 10/17/2008 Dcument Number: IC-0001 Dates Reviewed: 06/2009, 12/2009, 07/2010, 09/2010, 12/2010, 03/2011,
More informationOpdivo (nivolumab) (Intravenous)
Opdiv (nivlumab) (Intravenus) Last Review Date: 1/03/2018 Date f Origin: 01/06/2015 Dcument Number: IC-0226 Dates Reviewed: 03/2015, 07/2015, 10/2015, 11/2015, 02/2016, 05/2016, 08/2016, 10/2016, 11/2016,
More informationDrug Therapy Guidelines
Applicable* Medical Benefit x Effective: 2/15/19 Pharmacy- Frmulary 1 Next Review: 12/19 Pharmacy- Frmulary 2 Date f Origin: 4/1/05 Pharmacy- Frmulary 3/Exclusive Review Dates: 4/1/05, 2/1/06, 10/15/06,
More informationSERVICE DE GYNÉCOLOGIE-ONCOLOGIE PROTOCOLES EN RECRUTEMENT
SERVICE DE GYNÉCOLOGIE-ONCOLOGIE PROTOCOLES EN RECRUTEMENT OVAIRES PROTOCOLES PTES PHASE DESCRIPTION OV25 DP/GSO/GSO/FG 6 II PRÉVENTION A Randmized Phase II Duble-Blind Placeb-Cntrlled Trials f Acetylsalicylic
More informationVectibix (panitumumab) will be considered medically necessary when all of the following criteria are met:
What s New Medical Pharmaceutical Policy November 2017 Updates MBP 40.0 Orencia IV (abatacept)- New Indication Orencia IV (abatacept) will be considered medically necessary when all of the following criteria
More informationOpioid Analgesics PA Request Provider Checklist
WVP Health Authrity Updated 05-12-2015 Opiid Analgesics PA Request Prvider Checklist *** If pssible, please include the fllwing infrmatin with PA requests fr piid analgesics. Including the requested infrmatin
More informationBenefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria
Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Intravenus Vancmycin Use in Adults Intermittent (Pulsed) Infusin Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment
More informationPatient must be 18 years of age or older (unless otherwise specified); AND
(Intravenus) Last Review Date: January 1, 2019 Number: MG.MM.PH.89 Medical Guideline Disclaimer C All rights reserved. The treating physician r primary care prvider must submit t EmblemHealth the clinical
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745
Generic Brand HICL GCN Exceptin/Other NALTREXONE CONTRAVE ER 41389 /BUPROPION LORCASERIN BELVIQ 34733 PHENTERMINE PHENTERMINE 20691 20692 20693 20713 PHENTERMINE LOMAIRA 20715 PHENTERMINE/TO PIRAMATE GUIDELINES
More informationWound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018
Wund Care Equipment and Supply Benefits t Change fr Texas Medicaid July 1, 2018 Infrmatin psted May 11, 2018 Nte: Texas Medicaid managed care rganizatins (MCOs) must prvide all medically necessary, Medicaid-cvered
More informationUS Public Health Service Clinical Practice Guidelines for PrEP
Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S
More informationYescarta (axicabtagene ciloleucel) (Intravenous)
Yescarta (axicabtagene cilleucel) (Intravenus) Last Review Date: 10/31/2017 Date f Origin: 10/31/2017 Dates Reviewed: 10/2017 Dcument Number: IC-0333 I. Length f Authrizatin Cverage will be prvided fr
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment r prphylaxis. Evidence supprting this guidance is detailed belw.
More informationBariatric Surgery FAQs for Employees in the GRMC Group Health Plan
Bariatric Surgery FAQs fr Emplyees in the GRMC Grup Health Plan Gergia Regents Medical Center and Gergia Regents Medical Assciates emplyees and eligible dependents wh are in the GRMC Grup Health Plan (Select
More informationDrug Therapy Guidelines
Applicable Medical Benefit x Effective: 5/1/18 Pharmacy- Frmulary 1 x Next Review: 3/18 Pharmacy- Frmulary 2 x Date f Origin: 4/99 Gnadtrpin-Releasing Hrmne Agnists- Eligard, Luprn, Luprn-Dept, Luprn Dept-Ped,
More informationCSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009
CSHCN Services Prgram Benefits t Change fr Outpatient Behaviral Health Services Infrmatin psted Nvember 10, 2009 Effective fr dates f service n r after January 1, 2010, benefit criteria fr utpatient behaviral
More informationHealth Screening Record: Entry Level Due: August 1st MWF 150 Entry Year
Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic
More informationMy Symptoms and Medical History for Adult Chronic Immune Thrombocytopenia (ITP)
My Symptms and Medical Histry fr Adult Chrnic Immune Thrmbcytpenia (ITP) Call t talk t a registered nurse 1-855-7Nplate (1-855-767-5283), Mnday Friday, 9:00 AM 9:00 PM ET Indicatin Nplate is a man-made
More informationMEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache
MEASURE #10: PLAN OF CARE FOR MIGRAINE OR CERVICOGENIC HEADACHE DEVELOPED OR REVIEWED Headache Measure Descriptin All patients diagnsed with migraine headache r cervicgenic headache wh had a headache management
More informationUpdates to Medical Policies and Clinical UM Guidelines
Updates t Medical Plicies and Clinical UM Guidelines Effective May 1, 2016 The majr new plicies and changes are summarized belw. Please refer t the specific plicy fr cding, language, and ratinale updates
More informationRelated Policies None
Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER
More information2018 CMS Web Interface
CMS Web Interface MH-1 (NQF 0710): Depressin Remissin at Twelve Mnths Measure Steward: MNCM CMS Web Interface V2.0 Page 1 f 27 11/13/2017 Cntents INTRODUCTION... 4 CMS WEB INTERFACE SAMPLING INFORMATION...
More informationContinuous Positive Airway Pressure (CPAP) and Respiratory Assist Devices (RADs) including Bi-Level PAP
Cntinuus Psitive Airway Pressure (CPAP) and Respiratry Assist Devices (RADs), Including Bi-Level PAP Benefit Criteria t Change fr Texas Medicaid Effective March 1, 2017 Overview f Benefit Changes Benefit
More informationNCI Version Date: (194) NSABP B-55/BIG 6-13
Figure 1 Study Flw Chart ICF fr patients with unknwn BRCA status t underg central BRCA testing during, r prir t, neadjuvant/adjuvant chemtherapy Neadjuvant chemtherapy Minimum 6 cycles (cntaining anthracyclines,
More informationClinical Policy: Vedolizumab (Entyvio) Reference Number: ERX.SPA.163 Effective Date:
Clinical Plicy: Vedlizumab (Entyvi) Reference Number: ERX.SPA.163 Effective Date: 10.01.16 Last Review Date: 11.18 Revisin Lg See Imprtant Reminder at the end f this plicy fr imprtant regulatry and legal
More information2018 CMS Web Interface
CMS Web Interface MH-1 (NQF 0710): Depressin Remissin at Twelve Mnths Measure Steward: MNCM CMS Web Interface V2.1 Page 1 f 27 06/25/ Cntents INTRODUCTION... 4 CMS WEB INTERFACE SAMPLING INFORMATION...
More informationContinuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator
Cntinuus Quality Imprvement: Treatment Recrd Reviews Third Thursday Prvider Call (August 20, 2015) Wendy Bwlin, QM Administratr Gals f the Presentatin Review the findings f Treatment Recrd Review results
More informationJefferies 2014 Global Healthcare Conference. June 3, 2014
Jefferies 2014 Glbal Healthcare Cnference June 3, 2014 Frward Lking Statements This presentatin cntains certain frward lking statements relating t the cmpany s financial results, business prspects and
More informationCardiac Rehabilitation Services
Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin
More informationSignificance of Chronic Kidney Disease in 2015
1 Significance f Chrnic Kidney Disease in 2015 There is still a requirement within QOF t keep a register f peple with CKD stages 3-5. The ther CKD QOF targets have been retired. This is because CKD care
More informationHeart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or
Heart Failure (HF): Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD) (NQF 0081) EMeasure Name Heart Failure (HF): Angitensin
More information2017 Optum, Inc. All rights reserved BH1124_112017
1) What are the benefits t clients f encuraging the use f MAT? Withut MAT, 90% f individuals with Opiid Use Disrder (OUD) will relapse within ne year. With MAT, the relapse rate fr thse with OUD decreases
More informationHeart Failure (HF): Angiotensin Converting Enzyme (ACE) Inhibitor or
Heart Failure (HF): Angitensin Cnverting Enzyme (ACE) Inhibitr r Angitensin Receptr Blcker (ARB) Therapy fr Left Ventricular Systlic Dysfunctin (LVSD) (NQF 0081) EMeasure Name Heart Failure (HF): EMeasure
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Louisiana Healthcare Connections Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Luisiana Healthcare Cnnectins Prviders Questin GENERAL Why did Luisiana Healthcare Cnnectins implement a Medical Prgram? Answer
More informationPerjeta (pertuzumab) Document Number: IC I. Length of Authorization. Dosing Limits. Initial Approval Criteria
Perjeta (pertuzumab) Last Review Date: 11/21/2017 Date f Origin: 11/01/2012 Dcument Number: IC-0096 Dates Reviewed: 12/2012, 3/2013, 6/2013, 9/2013, 11/2013, 12/2013, 3/2014, 6/2014, 9/2014, 12/2014, 3/2015,
More informationProtocol Abstract and Schema
NCI Prtcl #: PBTC-042 Lcal Prtcl #: PBTC-042 Prtcl Abstract and Schema PBTC-042: Phase I study f CDK 4-6 inhibitr PD-0332991 (palbciclib; IBRANCE) in children with recurrent, prgressive r refractry central
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS)
Questin GENERAL Why did MHS implement a Medical Specialty Slutins Prgram? Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Managed Health Services (MHS) Answer Effective Nvember
More information2018 CMS Web Interface
PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease CMS Web Interface PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease Measure Steward: CMS CMS
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable* Hereditary Angiedema (HAE) Agents: Berinert (C1 esterase inhibitr [human]), Cinryze (C1 esterase inhibitr [human]), Haegarda (C1 esterase inhibitr [human]) Kalbitr (ecallantide),
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable Medical Benefit x Effective: 5/1/18 Pharmacy- Frmulary 1 x Next Review: 6/18 Pharmacy- Frmulary 2 x Date f Origin: 11/07 Immune Glbulins Intravenus: Carimune NF, Flebgamma,
More informationActemra (tocilizumab) (Intravenous)
Actemra (tcilizumab) (Intravenus) Last Review Date: 06/01/2018 Date f Origin: 09/21/2010 Dcument Number: MODA-0002 Dates Reviewed: 12/2010, 03/2011, 05/2011, 06/2011, 09/2011, 12/2011, 03/2012, 06/2012,
More informationPBTC-026: A Feasibility Study of SAHA Combined with Isotretinoin and Chemotherapy in Infants with Embryonal Tumors of the Central Nervous System
PBTC-026: A Feasibility Study f SAHA Cmbined with Istretinin and Chemtherapy in Infants with Embrynal Tumrs f the Central Nervus System PURPOSE: This clinical trial is studying the side effects f giving
More information23/11/2015. Introduction & Aims. Methods. Methods. Survey response. Patient Survey (baseline)
Intrductin & Aims Drug and Alchl Cnsultatin Liaisn (AOD CL) services aim t imprve identificatin and treatment f patients with AOD mrbidity. The csts and cnsequences f targeting AOD patients presenting
More informationUNM SRMC SLEEP MEDICINE CLINICAL PRIVILEGES.
Initial privileges (initial appintment) Renewal f privileges (reappintment) Expansin f privileges (mdificatin) INSTRUCTIONS All new applicants must meet the fllwing requirements as apprved by the UNM SRMC
More informationHigh Performance Network Quality Criteria for Designation
Selected quality measures include: Specialty Measure Descriptin Allergy / Immunlgy Asthma Drug Mgt Vaccine Pneumnia Vaccine High Perfrmance Netwrk Quality Criteria fr Designatin AvMed has selected certain
More information2017 CMS Web Interface
CMS Web Interface PREV-12 (NQF 0418): Preventive Care and Screening: Screening fr Depressin and Fllw-Up Measure Steward: CMS Web Interface V1.0 Page 1 f 22 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE
More informationLEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST
OPTUM LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY / APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED
More informationNIA Magellan 1 Spine Care Program Interventional Pain Management Frequently Asked Questions (FAQs) For Medicare Advantage HMO and PPO
NIA Magellan 1 Spine Care Prgram Interventinal Pain Management Frequently Asked Questins (FAQs) Fr Medicare Advantage HMO and PPO Questin GENERAL Why is Flrida Blue implementing a Spine Management prgram
More informationOriginal Policy Date 12:2013
MP 5.01.18 Xlair (Omalizumab) Medical Plicy Sectin Prescriptin Drugs Issu12:2013e 4:2006 Original Plicy Date 12:2013 Last Review Status/Date Lcal plicy/12:2013 Return t Medical Plicy Index Disclaimer Our
More informationOrencia (abatacept) Document Number: MODA-0091
Orencia (abatacept) Dcument Number: MODA-0091 Last Review Date: 09/19/2017 Date f Origin: 07/02/2010 Dates Reviewed: 07/2010, 09/2010, 12/2010, 02/15/11, 03/2011, 06/2011, 09/2011, 12/2011, 03/2012, 06/2012,
More informationShared Care Protocol for the prescribing and monitoring of maintenance doses of azathioprine in Inflammatory Bowel Disease
Apprved by the Bedfrdshire and Lutn Jint Prescribing Cmmittee (JPC) December 2013, Review date December 2016 Bedfrdshire and Lutn Jint Prescribing Cmmittee Shared Care Prtcl fr the prescribing and mnitring
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQ s) Fr PA Health & Wellness Prviders Questin GENERAL Why is PA Health & Wellness implementing a Medical Specialty Slutins Prgram? Answer
More informationCLINICAL MEDICAL POLICY
Plicy Name: Plicy Number: Respnsible Department(s): CLINICAL MEDICAL POLICY Supervised Exercise Therapy fr Peripheral Artery Disease (PAD) MP-077-MD-DE Medical Management Prvider Ntice Date: 01/15/2019
More informationSelect Oral Oncology Drugs
Select Oral Onclgy Drugs Plicy # 00642 Applies t all prducts administered r underwritten by Blue Crss and Blue Shield f Luisiana and its subsidiary, HMO Luisiana, Inc.(cllectively referred t as the Cmpany
More informationBreast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)
Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages
More information2017 CMS Web Interface
CMS Web Interface PREV-5 (NQF 2372): Breast Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More informationCoronary Artery Disease (CAD): Beta Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI) (NQF 0070)
Crnary Artery Disease (CAD): Beta Blcker Therapy fr CAD Patients with Prir Mycardial Infarctin (MI) (NQF 0070) EMeasure Name Crnary Artery Disease EMeasure Id Pending (CAD): Beta Blcker Therapy fr CAD
More informationDrug Therapy Guidelines
Applicable Medical Benefit x Effective: 1/1/18 Pharmacy- Frmulary 1 x Next Review: 12/18 Pharmacy- Frmulary 2 x Date f Origin: 5/28/06 Pulmnary Arterial Hypertensin : Revati (sildenafil), Ventavis (ilprst),
More informationEAGLE CARE A SPORT CLUB CONCUSSION MANAGEMENT MODEL
EAGLE CARE A SPORT CLUB CONCUSSION MANAGEMENT MODEL Cncussin awareness has increased significantly in recent years. The Natinal Cllegiate Athletic Assciatin (NCAA), Natinal Athletic Trainers Assciatin
More informationBANKMED MEDICAL SCHEME. MEDICINE ADVISORY SERVICES (Chronic Medicine Benefit) GENERAL INFORMATION
BANKMED MEDICAL SCHEME MEDICINE ADVISORY SERVICES (Chrnic Medicine Benefit) GENERAL INFORMATION LIST OF CHRONIC CONDITIONS Cnditins cvered under Bankmed s chrnic medicatin benefit are detailed belw. REGISTRATION
More informationUpdates to Medical Policies Effective October 1, 2017 and November 1, 2017
Updates t Medical Plicies Effective Octber 1, 2017 and Nvember 1, 2017 The majr new plicies and changes are summarized belw, and additinal updates are in Attachment A. Please refer t the specific plicy
More information2018 CMS Web Interface
CMS Web Interface PREV-12 (NQF 0418): Preventive Care and Screening: Screening fr Depressin and Measure Steward: CMS CMS Web Interface V2.1 Page 1 f 23 06/25/ Cntents INTRODUCTION... 3 CMS WEB INTERFACE
More informationHearing Service Fees and Fee Codes Effective: January 01, 2019
Hearing Fees and Fee Cdes Effective: January 01, 2019 The WCB will fund the fllwing hearing services fr claims accepted fr traumatic and ccupatinal nise induced hearing: Fee cde 200 - Full audilgical assessment.
More informationP02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017
P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...
More information<Date> <Group> <Address1> <Address2> <City> <State> <zip> RE: 2015 Blue Physician Recognition (BPR) Program. Dear <Group>:
Three Penn Plaza East Newark, NJ 07105-2200 HriznBlue.cm RE: 2015 Blue Physician Recgnitin (BPR) Prgram Dear : Hrizn Blue Crss Blue Shield
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial infrmatin prvided in this public disclsure synpsis is supplied fr infrmatinal purpses nly. Please nte that the results reprted in any single trial may nt reflect the verall ptential
More informationCognitive enhancers for the treatment of Alzheimer s disease
Cmprehensive Research Plan: Cgnitive enhancers fr the treatment f Alzheimer s disease Pharmacepidemilgy Unit February 13 th, 2015 30 Bnd Street, Trnt ON, M5B 1W8 www.dprn.ca inf@dprn.ca 2 ODPRN Drug Class
More informationMEDICARE COVERAGE SUMMARY: TRANSCRANIAL MAGNETIC STIMULATION
OPTUM MEDICARE COVERAGE SUMMARY: TRANSCRANIAL MAGNETIC STIMULATION MEDICARE COVERAGE SUMMARY: TRANSCRANIAL MAGNETIC STIMULATION Guideline Number: Effective Date: April, 2018 INSTRUCTIONS FOR USE This guideline
More information2017 CMS Web Interface
CMS Web Interface PREV-6 (NQF 0034): Clrectal Cancer Screening Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION... 4 BENEFICIARY
More information2018 CMS Web Interface
CMS Web Interface PREV-13: Statin Therapy fr the Preventin and Treatment f Cardivascular Disease Measure Steward: CMS CMS Web Interface V2.1 Page 1 f 27 06/25/ Cntents INTRODUCTION... 4 CMS WEB INTERFACE
More informationThis Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.
This Cverage Plicy applies t Individual Health Insurance Marketplace benefit plans nly. Immunlgical Agents Bilgical Respnse Mdifier-Tumr Necrsis Factr (TNF) Inhibitrs: Enbrel (etanercept fr subcutaneus
More informationChimeric Antigen Receptor T cell Therapy (CAR-T)
Applies t all prducts administered r underwritten by Blue Crss and Blue Shield f Luisiana and its subsidiary, HMO Luisiana, Inc.(cllectively referred t as the Cmpany ), unless therwise prvided in the applicable
More informationCommissioning Policy: South Warwickshire CCG (SWCCG)
Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding
More informationPennsylvania Guidelines on the Use of Opioids to Treat Chronic Noncancer Pain
Pennsylvania Guidelines n the Use f Opiids t Treat Chrnic Nncancer Pain Chrnic pain is a majr health prblem in the United States, ccurring with a pintprevalence f abut ne-third f the US ppulatin.(1) Mre
More informationedaravone (Radicava )
Applies t all prducts administered r underwritten by Blue Crss and Blue Shield f Luisiana and its subsidiary, HMO Luisiana, Inc.(cllectively referred t as the Cmpany ), unless therwise prvided in the applicable
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic nts Original Policy Date: January 16, 2015 Subject: Opdivo Page: 1 of
More informationDrug Class Review: Long-acting muscarinic antagonists (LAMAs) for treatment of chronic obstructive pulmonary disease (COPD)
Drug Class Review: Lng-acting muscarinic antagnists (LAMAs) fr treatment f chrnic bstructive pulmnary disease (COPD) Cmprehensive Research Plan: Pharmacepidemilgy Unit April 10 th, 2014 ODPRN Drug Class
More informationPhysical, Occupational, and Speech Therapy - Children (Acute and Chronic)
Physical, Occupatinal, and Speech Therapy - Children (Acute and Chrnic) Infrmatin psted May 6, 2016 Nte: This article applies t claims submitted t TMHP fr prcessing. Fr claims prcessed by a Medicaid managed
More informationWARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES
INDICATION FARYDAK (panbinstat) capsules, a histne deacetylase inhibitr, in cmbinatin with brtezmib and dexamethasne, is indicated fr the treatment f patients with multiple myelma wh have received at least
More informationShared Care Protocol for the prescribing and monitoring of maintenance doses of azathioprine in Inflammatory Bowel Disease
Bedfrdshire and Lutn Jint Prescribing Cmmittee Shared Care Prtcl fr the prescribing and mnitring f maintenance dses f azathiprine in Inflammatry Bwel Disease This prtcl applies t patients under the care
More informationSpecifically, on page 12 of the current evicore draft, we find the statement:
Octber 23, 2016 evicre Healthcare Attn: Dr Greg Allen 400 Buckwalter Place Bulevard Blufftn, SC 29910 RE: evicre Draft Onclgy Imaging Guidelines, v 19.0 Gentlepersns: Prstate Cancer Internatinal is a nt-fr-prfit
More informationP&T Committee Meeting Minutes GHP Family January 15, 2019
P&T Cmmittee Meeting Minutes GHP Family January 15, 2019 Present: Bret Yarczwer, MD, MBA Chair Kristen Bender, PharmD via phne Rajneel Chhan Pharm.D. Alyssa Cilia, RPh via phne Kimberly Clark, PharmD Kristi
More information2017 CMS Web Interface
CMS Web Interface CARE-2 (NQF 0101): Falls: Screening fr Future Fall Risk Measure Steward: NCQA Web Interface V1.0 Page 1 f 18 11/15/2016 Cntents INTRODUCTION... 3 WEB INTERFACE SAMPLING INFORMATION...
More information